AbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market

Since they were approved four months apart in 2019, AbbVie’s Skyrizi and Rinvoq have been joined at the hip, central to the Illinois drugmaker's hopes that the duo could replace aging immunology su | Seven years after it was approved, AbbVie's Skyrizi has proven to be a more-than-adequate replacement for Humira, which was formerly the world's top-selling drug. In the second quarter, the IL-23 inhibitor generated sales of $5.55 billion, a virtual match for the most ever achieved by Humira in a single quarter.